S
SS-31
SS-31 is a synthetic tetrapeptide designed to target and protect mitochondria, the cellular structures responsible for energy production
SS-31 has shown promise for conditions linked to mitochondrial dysfunction, including:
Kidney Diseases: Protects against ischemia-reperfusion injury, diabetic nephropathy, and age-related glomerulosclerosis reducing oxidative stress and improving mitochondrial morphology
Cardiovascular Diseases: Improves cardiac function, reduces ischemia/reperfusion injury, and stabilizes atherosclerotic plaques. It enhances ATP production and reduces ROS in heart failure models
Neurodegenerative Disorders: Mitigates oxidative stress and inflammation in the hippocampus, improving memory and cognitive function in models of Alzheimer’s, Parkinson’s, and lipopolysaccharide-induced cognitive deficits
Mitochondrial Myopathies: Enhances energy production and reduces symptoms in primary mitochondrial diseases, with orphan drug designations for mitochondrial myopathy
Age-Related Conditions: Improves exercise tolerance, muscle mass, and fatigue resistance, suggesting anti-aging potential by restoring mitochondrial energetics
SS-31 also shows therapeutic potential in migraine, pulmonary fibrosis, and burn injury recovery by reducing apoptosis and oxidative damage
Research application
Copied from the handbook as research notes. and not instructions.
- 10 mg vial SS-31
- Reconstitution volume: 2mL of BAC water
- 2mg = 40 units
- 4mg = 80 units
- 6mg = 120 units
- 1-10mg doses per day are common
Unless other wise noted intermuscular (IM) peptides are commonly administered via subcutaneous (SQ) injection with 30-31 gauge syringes
From @BowTiedYukon